Related Experiment Videos
Evaluation of a workplace hemochromatosis screening program.
G M Stave1, J J Mignogna, G S Powell
1Glaxo Wellcome Inc., Research Triangle Park, NC 27709, USA.
American Journal of Preventive Medicine
|September 24, 1999
Summary
Workplace screening for hemochromatosis (an inherited iron metabolism disorder) is cost-effective. This corporate program identified individuals with the condition, demonstrating its value in disease prevention for employees.
Area of Science:
- Occupational Health
- Genetics and Inherited Diseases
- Public Health Screening
Background:
- Hemochromatosis is a prevalent inherited iron metabolism disorder with serious health implications.
- Despite recommendations, workplace screening for hemochromatosis is not widespread.
- Corporate screening programs can identify at-risk employees.
Purpose of the Study:
- To evaluate the cost-effectiveness of a corporate hemochromatosis screening program.
- To assess the feasibility and yield of workplace screening for this condition.
- To identify barriers to diagnosis and suggest improvements.
Main Methods:
- A corporate screening program tested 1968 employees.
- The algorithm involved serum iron, transferrin, and ferritin level measurements.
- Elevated ratios triggered ferritin tests; positive results led to diagnostic evaluations.
Main Results:
- 13% of men and 21% of women had elevated iron/transferrin ratios.
- 16 employees (14 men, 2 women) showed elevated ferritin levels.
- Three individuals underwent liver biopsies, confirming hemochromatosis in all cases.
Conclusions:
- Workplace hemochromatosis screening is highly cost-effective, with a cost per year of life saved of $928.
- The program's cost per diagnosis was $9283, comparing favorably to other workplace screenings.
- Integrating this screening into corporate health programs is recommended to enhance disease prevention.